AI Science Tracker

Qilu Hospital of Shandong University

1 discovery from 2026

Discoveries

M3-CAD designs antimicrobial QLX-3DV peptides

M3-CAD combines sequence, predicted structural and physicochemical features in a multimodal peptide-design pipeline. The journal study reports in-vitro activity for selected QLX-3DV peptides, including untemplated candidates, against tested bacterial strains; selected leads also received additional host-toxicity and mouse wound-infection assays. These are selected preclinical results, not evidence of clinical efficacy or safety. The article cites an earlier M3-CAD/QL-AMP-1 preprint; this entry is restricted to the reported QLX-3DV study result and does not claim the pipeline itself as new.

Technology: M3-CAD multimodal deep-learning pipeline

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Selected designed peptides were synthesized and tested in vitro; selected leads were also examined in mouse wound infection and host-toxicity assays.
  • Still unknown: Clinical efficacy and safety, independent replication and full sequence-level comparison with the earlier M3-CAD preprint are not established here.
  • AI role: M3-CAD uses multimodal learned sequence and predicted-structure representations with activity-related objectives to generate and rank peptides for experimental testing.

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13185819/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 16 Nov 2026. Review scope: Primary PMC full text including publication metadata, methods and experimental results..

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.